Fulcrum Therapeutics, Inc. - Common Stock, par value $0.001 per share (FULC)

Historical Holders from Q3 2019 to Q3 2025

Symbol
FULC on Nasdaq
CUSIP
359616109
Type / Class
Equity / Common Stock, par value $0.001 per share
Shares outstanding
54M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
53.8M
Holdings value
$495M
% of all portfolios
0.001%
Grand Portfolio weight change
0%
Number of holders
126
Number of buys
62
Number of sells
-61
Average Value change %
0%
Average buys %
+0%
Average sells %
-0.001%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Fulcrum Therapeutics, Inc. - Common Stock, par value $0.001 per share (FULC)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
SUVRETTA CAPITAL MANAGEMENT, LLC 9.4% +51.7% $18.5M $6.07M 5.07M +48.8% SUVRETTA CAPITAL MANAGEMENT, LLC Mar 31, 2025
Nantahala Capital Management, LLC 7.66% $17.4M 4.78M Nantahala Capital Management, LLC Sep 30, 2024
BlackRock, Inc. 6% -18.8% $30.1M -$7.02M 3.27M -18.9% BlackRock, Inc. Sep 30, 2025
Adage Capital Management, L.P. 4.5% -44.4% $22.4M -$19.8M 2.43M -47% Adage Capital Management, L.P. Sep 30, 2025

Institutional Holders of Fulcrum Therapeutics, Inc. - Common Stock, par value $0.001 per share (FULC)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 53.8M $495M -$1.39M $9.20 126
2025 Q2 54.4M $374M +$23.5M $6.88 122
2025 Q1 51.3M $148M -$3.07M $2.88 115
2024 Q4 51.7M $243M -$8.31M $4.70 117
2024 Q3 54.9M $196M -$86.4M $3.57 132
2024 Q2 64.8M $401M +$19.7M $6.20 124
2024 Q1 60.3M $570M -$2.97M $9.44 122
2023 Q4 61.1M $412M +$14M $6.75 99
2023 Q3 56.4M $250M +$9.02M $4.44 80
2023 Q2 55.5M $183M -$14.2M $3.30 86
2023 Q1 60.4M $172M +$51.6K $2.85 116
2022 Q4 50.6M $368M -$13.1M $7.28 109
2022 Q3 52.2M $422M +$98.7M $8.09 103
2022 Q2 40.1M $197M -$32.7M $4.90 100
2022 Q1 39.1M $924M +$64.7M $23.65 106
2021 Q4 37.2M $657M -$42.8M $17.69 109
2021 Q3 36.6M $1.03B +$305M $28.21 102
2021 Q2 26.8M $281M -$3.28M $10.48 66
2021 Q1 26.9M $317M +$45.6M $11.78 68
2020 Q4 22.2M $260M +$20.2M $11.71 65
2020 Q3 20.6M $163M -$36.9M $7.93 53
2020 Q2 20.5M $374M +$66.4M $18.29 60
2020 Q1 16.8M $201M +$11.9M $11.94 46
2019 Q4 15.8M $262M +$1.37M $16.64 38
2019 Q3 15.9M $105M +$105M $6.64 39